View
389
Download
1
Category
Preview:
DESCRIPTION
Doron Ben Meir delivered the presentation at the 2014 Future of Medical Research Conference. The 2014 Future of Medical Research Conference allowed industry professionals to address questions regarding the future of medical research in Australia, with key topics including what the current focus in the industry is, how to best generate funding, what the latest innovations are, and how to commercialise the research into treatments and cures. For more information about the event, please visit: http://bit.ly/futuremed14
Citation preview
Doron Ben-Meir
Director, Entrepreneurs’ Infrastructure Programme30 July 2014
The Future of Medical Research
Commercialisation
R&D (Invention)
Commercialisation
IPIP
$$
$$$$$$$$$$
The final value proposition for new IP is rarely clear at the outset
”
”
Supporting the commercialisation of novel intellectual property with commercial potential. It will provide access to appropriately skilled, experienced and independent Commercialisation Advisors, facilitate critical business connections through networking opportunities and offer targeted financial assistance.
Entrepreneurial Infrastructure
Funding Sources
Customers
Founders, Family and
Friends
Angels High Net-Worth
Strategic Corporates
Venture Capital Debt
Crowd Funding
Public Markets
Piecing it together
Western Australia3 Commercialisation Advisers
70 Participants
South Australia & the NT
3 Commercialisation Advisers37 SA + 3 NT Participants
Queensland 5 Commercialisation Advisers 151 Participants
New South Wales & ACT8 Commercialisation Advisers139 NSW Participants16 ACT Participants
Victoria & Tasmania6 Commercialisation Advisers134 VIC + 14 TAS Participants
Supporting a national portfolio of 500+ Companies and Researchers
A national network of Advisers
Growing Expert Network
As at July 2014
The Portfolio
As at July 2014
Biotechnology12%
Software & Web Design
34%
Computer Sys-tems
& Hardware12%
Manufacturing, Engineering &
Design42%
Value by key technology
Value by target market
As at July 2014
Agriculture and Food
Automotive, Aviation and Marine
Business and Communications
Defence, Security and Safety
Education and Training
Energy, Mining and Resources
Entertainment, Tourism and Sport
Health and Medical
Infrastructure and Building
OEM
Textiles, Clothing and Footwear
0 10000000 20000000 30000000 40000000 50000000 60000000
Endoluminal Pty Ltd
• Sydney medical technology company based on founders' research from Stanford & Sydney Universities
• Sealing technology for minimally invasive aortic valve replacement surgery - will prevent valve leakage which occurs in up to 50% of patients undergoing surgery
• Initial $227,500 grant
• License agreement with Swiss company Symetis SA in September 2013
Case Study
Admedus (formerly Celxcel Pty Ltd)
• Perth based biotechnology company
• Developed CardioCel®, a regenerative tissue product that treats and repairs congenital heart defects
• $1.9 million grant • In late 2013 Admedus raised
$10.4 million through a rights offer
• In February 2014 the US Federal Drug Administration approved the sale of CardioCel® in the US
Case Study
ElisaKit.com Pty Ltd
• Melbourne based biotech company
• Developed new process for the economic manufacture of ELISA (Enzyme-linked immunosorbent assay) kits that leverages innovative experimental design, statistical modelling and lean manufacturing
• Plan to market the kits in Australia and overseas
• $270,000 grant
Case Study
Global Kinetics Corporation Pty Ltd
Case Study
• Melbourne based medical technology company
• Developed Parkinson's KinetiGraph (PKG) System, a unique solution for neurologists in the management of Parkinson's disease symptoms
• PKG remotely records patient symptoms and reports this information to health professionals, allowing them to optimize drug performance
• The system also reminds the patient when to take their medication
• $400,000 grant
Nexvet Biopharma Pty Ltd
Case Study
• Melbourne based biotechnology company
• Developed a safe and effective therapeutic platform of biological drugs to treat dogs, cats and horses
• $300,000 grant• Raised $7 million in October 2013• In April 2014, Nexvet raised $31.5 million
from top-tier US-based investors including Farallon Capital Management, LLC, Adage Capital Partners, LP, Foresite Capital and Tavistock Life Sciences subsidiary fund, Boxer Capital.
PolyActiva Pty Ltd
• Melbourne biotech company • Developed a unique drug-polymer
technology for new biomedical products and device components, enabling drug delivery direct to organs
• $250,000 grant • Raised $9.2 million in a Series B
financing round from a consortium of investors including the Medical Research Commercialisation Fund, Brandon Capital, Yuuwa Capital and angel investors
Case Study
Contact Us
Web: www.Business.gov.auPhone: 13 28 46
Recommended